Passkey Therapeutics

Metabolic Passkey Therapeutics is dedicated to the discovery of new medicines targeting complex diseases with multifactorial causes. The company operates in the pharmaceutical sector, focusing on metabolic diseases such as lipid disorders, obesity, and diabetes, as well as various forms of cancer. Utilizing a Rational Polypharmacology platform, Passkey leverages recent advances in computational and genomic methods to develop novel therapeutics. The business model centers on creating drugs that address the intricate interplay of biological pathways influenced by genetics and the environment. By targeting the molecular and cellular mechanisms of disease, Passkey aims to produce treatments with superior efficacy and fewer side effects compared to conventional therapies. The company serves healthcare providers and patients affected by these widespread and inadequately treated conditions. Keywords: drug discovery, metabolic diseases, cancer, Rational Polypharmacology, genomic methods, lipid disorders, obesity, diabetes, tumor biology, novel therapeutics.